Enrolling

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

J4E-MC-FR01 -

The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).

Enter your city or zip code to find the nearest site

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
18 - 70 years
Conditions the trial is for
Atopic Dermatitis (Eczema)
What the trial is testing?
Ucenprubart
Could I receive a Placebo?
Yes
Enrollment Goal
260
Trial Dates
Jun 21, 2023 - May 2025
How long will I be in the trial?
The study will last about 52 weeks and may include up to 19 visits.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have active atopic dermatitis for over a year and include the following:

    • EASI score ≥ 12 at first dosing visit

    • vIGA-AD score ≥3 at first dosing visit

  • Have ≥10% of BSA involvement (per EASI BSA) at first dosing visit

  • Have little improvement with topical medicines

Participants Must Not:

  • Have any prior skin infections requiring treatment with topical corticosteroids

  • Have history of psoriasis

  • Have other infections such as Hepatitis B or C

  • Known allergy to study drug or any components to formulation or history of drug hypersensitivity reactions

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources